Nanobiotix SA
PAR:NANO
Nanobiotix SA
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
J&J Partnership: Nanobiotix's collaboration with Johnson & Johnson is progressing well, with J&J taking financial and operational lead on key NBTXR3 trials.
Financials: The company reported a net loss of EUR 68.1 million in 2024, primarily due to a noncash, one-off negative revenue item related to the transfer of NANORAY-312 to J&J.
Cash Runway: Cash and cash equivalents were EUR 49.7 million at year-end 2024, funding operations into mid-2026, with plans to extend runway into 2027 through nondilutive options.
R&D Pipeline: Clinical pipeline is advancing, with key data expected in 2024 and 2025 for head and neck, lung, and pancreatic cancers.
Cost Structure: Most Phase III costs for NANORAY-312 have been shifted to J&J, significantly lowering Nanobiotix's future R&D burn.
New Platform: The Curadigm nanotherapeutic platform was launched, with internal development and ongoing partnership discussions.
